The safety profile of tadalafil as prescribed in general practice in England: results from a prescription‐event monitoring study involving 16 129 patients

To examine the safety of tadalafil as used in general practice in England, and to compare the mortality rate due to ischaemic heart disease (IHD) in tadalafil users with that in the male population in England.

[1]  L. Hazell,et al.  An observational cohort study investigating the cardiovascular safety of tadalafil when prescribed in primary care in England: mortality due to ischaemic heart disease , 2007, BJU international.

[2]  A. Bella,et al.  Non-arteritic anterior ischemic optic neuropathy (NAION) and phosphodiesterase type-5 inhibitors. , 2006, The Canadian journal of urology.

[3]  R. Kloner,et al.  Cardiovascular effects of phosphodiesterase 5 inhibitors. , 2006, Current pharmaceutical design.

[4]  R. Kloner,et al.  Cardiovascular safety update of Tadalafil: retrospective analysis of data from placebo-controlled and open-label clinical trials of Tadalafil with as needed, three times-per-week or once-a-day dosing. , 2006, The American journal of cardiology.

[5]  L. Gorkin,et al.  Sildenafil citrate use and the incidence of nonarteritic anterior ischemic optic neuropathy , 2006, International journal of clinical practice.

[6]  S. Hayreh.  Erectile dysfunction drugs and non-arteritic anterior ischemic optic neuropathy: is there a cause and effect relationship? , 2005, Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society.

[7]  D. Hatzichristou.  INVITED COMMENTARYINVITED COMMENTARY: Phosphodiesterase 5 Inhibitors and Nonarteritic Anterior Ischemic Optic Neuropathy (NAION): Coincidence or Causality? , 2005 .

[8]  Frederick W. Fraunfelder,et al.  Visual side effects associated with erectile dysfunction agents. , 2005, American journal of ophthalmology.

[9]  R. Kloner,et al.  Pharmacotherapy of erectile dysfunction: focus on cardiovascular safety , 2005, Expert opinion on drug safety.

[10]  G. Jackson,et al.  Endothelial dysfunction links erectile dysfunction to heart disease , 2005, International journal of clinical practice.

[11]  J. Orazem,et al.  CLINICAL TRIALS OF SILDENAFIL CITRATE (VIAGRA®) DEMONSTRATE NO INCREASE IN RISK OF MYOCARDIAL INFARCTION AND CARDIOVASCULAR DEATH COMPARED WITH PLACEBO , 2003, International journal of clinical practice.

[12]  PDE5 inhibitors: looking beyond ED , 2003, International Journal of Clinical Practice.

[13]  S. Shakir,et al.  Cardiovascular events in users of sildenafil: results from first phase of prescription event monitoring in England , 2001, BMJ : British Medical Journal.

[14]  G. Smith,et al.  Sex and death: are they related? Findings from the Caerphilly cohort study , 1997 .

[15]  L. Johnson,et al.  Incidence of Nonarteritic and Arteritic Anterior Ischemic Optic Neuropathy: Population‐Based Study in the State of Missouri and Los Angeles County, California , 1994, Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society.

[16]  W. Inman.  PRESCRIPTION EVENT MONITORING , 1986, The Lancet.

[17]  R. Kloner,et al.  The second Princeton consensus on sexual dysfunction and cardiac risk: new guidelines for sexual medicine. , 2006, The journal of sexual medicine.

[18]  Bo Qing.  International ethical guidelines for biomedical research involving human subjects , 2003 .

[19]  D. Hodge,et al.  Incidence of nonarteritic anterior ischemic optic neuropathy. , 1997, American journal of ophthalmology.

[20]  G. Davey Smith,et al.  Sex and death: are they related? Findings from the Caerphilly Cohort Study. , 1997, BMJ.

[21]  D. Hodge,et al.  Incidence of Nonarteritic Anteripr Ischemic Optic Neuropathy , 1997 .